146 related articles for article (PubMed ID: 11304895)
1. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
Sadler BM; Chittick GE; Polk RE; Slain D; Kerkering TM; Studenberg SD; Lou Y; Moore KH; Woolley JL; Stein DS
J Clin Pharmacol; 2001 Apr; 41(4):386-96. PubMed ID: 11304895
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
Sadler BM; Hanson CD; Chittick GE; Symonds WT; Roskell NS
Antimicrob Agents Chemother; 1999 Jul; 43(7):1686-92. PubMed ID: 10390223
[TBL] [Abstract][Full Text] [Related]
3. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
Veronese L; Rautaureau J; Sadler BM; Gillotin C; Petite JP; Pillegand B; Delvaux M; Masliah C; Fosse S; Lou Y; Stein DS
Antimicrob Agents Chemother; 2000 Apr; 44(4):821-6. PubMed ID: 10722476
[TBL] [Abstract][Full Text] [Related]
6. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
Fung HB; Kirschenbaum HL; Hameed R
Clin Ther; 2000 May; 22(5):549-72. PubMed ID: 10868554
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
[TBL] [Abstract][Full Text] [Related]
9. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].
Janus N; Launay-Vacher V; Izzedine H; Karie S; Laville I; Deray G
Med Mal Infect; 2007 Dec; 37(12):832-4. PubMed ID: 17997253
[TBL] [Abstract][Full Text] [Related]
12. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
13. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
[TBL] [Abstract][Full Text] [Related]
14. Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
Yogev R; Kovacs A; Chadwick EG; Homans JD; Lou Y; Symonds WT
Antimicrob Agents Chemother; 2005 Jan; 49(1):336-41. PubMed ID: 15616313
[TBL] [Abstract][Full Text] [Related]
15. Amprenavir.
Adkins JC; Faulds D
Drugs; 1998 Jun; 55(6):837-42; discussion 843-4. PubMed ID: 9617598
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
Sadler BM; Gillotin C; Lou Y; Stein DS
Antimicrob Agents Chemother; 2001 Jan; 45(1):30-7. PubMed ID: 11120940
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Blight AR; Henney HR
Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
[TBL] [Abstract][Full Text] [Related]
18. Excretion balance and pharmacokinetics following a single oral dose of [
Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology and pharmacokinetics of amprenavir.
Sadler BM; Stein DS
Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
